Ke Liang-Yin, Stancel Nicole, Bair Henry, Chen Chu-Huang
Vascular and Medicinal Research, Texas Heart Institute, 6770 Bertner Avenue, Houston, TX, 77030, USA,
Curr Atheroscler Rep. 2014 Aug;16(8):428. doi: 10.1007/s11883-014-0428-y.
Electronegative low-density lipoprotein (LDL) found in human plasma is highly atherogenic, and its level is elevated in individuals with increased cardiovascular risk. In this review, we summarize the available data regarding the elevation of the levels of electronegative LDL in the plasma of patients with various diseases. In addition, we discuss the harmful effects and underlying mechanisms of electronegative LDL in various cell types. We also highlight the known biochemical properties of electronegative LDL that may contribute to its atherogenic functions, including its lipid and protein composition, enzymatic activities, and structural features. Given the increasing recognition of electronegative LDL as a potential biomarker and therapeutic target for the prevention of cardiovascular disease, key future goals include the development of a standard method for the detection of electronegative LDL that can be used in a large-scale population survey and the identification and testing of strategies for eliminating electronegative LDL from the blood.
在人体血浆中发现的带负电低密度脂蛋白(LDL)具有高度致动脉粥样硬化性,其水平在心血管风险增加的个体中会升高。在本综述中,我们总结了有关各种疾病患者血浆中带负电LDL水平升高的现有数据。此外,我们讨论了带负电LDL在各种细胞类型中的有害作用及潜在机制。我们还强调了带负电LDL已知的生化特性,这些特性可能有助于其致动脉粥样硬化功能,包括其脂质和蛋白质组成、酶活性及结构特征。鉴于带负电LDL作为预防心血管疾病的潜在生物标志物和治疗靶点越来越受到认可,未来的关键目标包括开发一种可用于大规模人群调查的检测带负电LDL的标准方法,以及识别和测试从血液中消除带负电LDL的策略。